Joris van de Haar - Concepedia

Author

Joris van de Haar

The Netherlands Cancer Institute ORCID

Also Known As

Haar, Joris van de, J. Van De Haar, J. van de Haar, Joris Van de Haar, Joris van de Haar

112

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute Oncode Institute Leiden University Medical Center University Medical Center Utrecht Hartwig Medical Foundation

About

Joris van de Haar is an author at The Netherlands Cancer Institute specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	2.4K
2	Cell Biology	2	2	1K
3	Engineering	1	1	73
4	Health Sciences	1	1	32
5	Cellular Therapies	1	1	1K

Joris van de Haar

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids Krijn K. Dijkstra, Chiara M. Cattaneo, Fleur Weeber, Cell Tumor-reactive T CellsCell TherapyCancer ImmunosurveillancePeripheral Blood LymphocytesT-regulatory Cell	2018	1K
Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients Salo Ooft, Fleur Weeber, Krijn K. Dijkstra, Science Translational Medicine Gastrointestinal OncologyPdo TestMedicineColorectal CancerPathology	2019	769
MHC-I Genotype Restricts the Oncogenic Mutational Landscape Rachel Marty, Saghar Kaabinejadian, David Rossell, Cell ImmunogeneticsAllelic VariantSomatic VariantGeneticsMolecular Genetics	2017	356
γδ T cells are effectors of immunotherapy in cancers with HLA class I defects N. de Vries, Joris van de Haar, Vivien Veninga, Nature	2023	265
A pan-cancer analysis of the microbiome in metastatic cancer Thomas Battaglia, Iris Mimpen, Joleen J.H. Traets, Cell	2024	162
Prospective experimental treatment of colorectal cancer patients based on organoid drug responses Salo Ooft, Fleur Weeber, Luuk J. Schipper, ESMO Open OncologyMedicineOrganoid Drug ResponsesColorectal CancerColorectal Cancer Patients	2021	135
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial Y.L. Verschoor, Joris van de Haar, José G. van den Berg, Nature Medicine	2024	93
Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment Louisa R. Hoes, Jade M. van Berge Henegouwen, Hanneke van der Wijngaart, Clinical Cancer Research	2022	79
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer Joris van de Haar, Xuhui Ma, Salo Ooft, Nature Medicine	2023	74
Limited evolution of the actionable metastatic cancer genome under therapeutic pressure Joris van de Haar, Louisa R. Hoes, Paul Roepman, Nature Medicine OncologyEngineeringSomatic VariantTumor HeterogeneityMedicine	2021	73

Page 1